about
N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in ratsComparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension.Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension.Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.Pharmacokinetic evaluation of continuous intravenous epoprostenol.Calcium-channel blockers in pulmonary arterial hypertension.Targeted therapies in pulmonary arterial hypertension.Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension.Chemotherapy-induced pulmonary hypertension: role of alkylating agents.New pharmacotherapy options for pulmonary arterial hypertension.Interferon-induced pulmonary hypertension: an update.Pulmonary arterial hypertension induced by tyrosine kinase inhibitors.Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge.Pulmonary arterial hypertension in patients treated with interferon.Pulmonary arterial hypertension in patients treated with interferon.Animal model methodology: immunocompetent or leucopenic rats, which is the best? Results from a model of experimental pneumonia due to derepressed cephalosporinase-producing Enterobacter cloacae.Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension.Pulmonary hypertension associated with benfluorex exposure.Unusual pharmacokinetics of intravitreal and systemic voriconazole in a patient with Scedosporium apiospermum endophthalmitis.Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study.Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity.Lung transplantation for mitomycin-induced pulmonary veno-occlusive disease.Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models.Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy.Lorlatinib - Induced pulmonary arterial hypertension.Nouvelles approches immunopathologiques de l’hypertension artérielle pulmonaireDexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in ratsResponse to Letter Regarding Article, “Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model”A study of magnesium deficiency in human and experimental pulmonary hypertensionPrevalence of drug-related problems associated with direct oral anticoagulants in hospitalized patients: a multicentre, cross-sectional studyEvaluation of a program of pharmaceutical counseling for French patients on oral anticoagulant therapy
P50
Q33786092-192BA302-B728-4963-B2C1-2E18902A4611Q34508259-1B22D2AF-6C83-45C3-AACE-2C9641B5B80CQ34997388-643AFC08-A72E-4BBB-9E4C-955BDAB4CD7CQ35289907-DFF87B16-25C9-4AFE-A796-82BFC03F53C4Q37217507-B09248FC-58A4-4B58-A6B4-EEBD0FD9A5EFQ37410202-2C5369ED-66C5-47C4-B725-5D852695418FQ37809538-53B1E94C-0AF8-461D-9053-A1F1B8C0B9DCQ38149027-D3A087CC-4618-43B6-950C-A4604DA3951BQ38153497-89E6A502-481B-4A01-9944-1038B8D348D5Q38271119-9AD4202F-F3A3-4903-BACC-3867C46C5FD2Q38286586-066C5324-6997-4E77-BE9E-2B31F319AD17Q38569940-DF2AA258-6C48-49F7-A0C1-101E242FCB3DQ38888820-B777CE1A-0670-416D-A941-711E8D6B8582Q39390665-2BDEEFE8-89CD-4376-B42A-C93F234D589AQ40105015-4DEACEA4-FF1F-4A06-934B-B9E112ADD05DQ41064083-82AB7C8F-C467-4EEE-B3F0-1B45D001E8E0Q41697963-80B762E3-89EF-4886-A275-C3697A4A0F6DQ44448806-85DE10FB-55DB-4AA5-A872-95F5CAC64A4CQ44917117-E82BE142-71CF-4923-A22D-405F72ED3EDEQ45334733-DA7ED6D8-3465-4EF3-8E82-FCEC9496006EQ46604185-3F5BB77D-24CE-487D-821F-51713FA86694Q46679061-3F3438B4-B7EA-411D-827C-BB7DB3A19541Q48154641-49044F82-39EA-4D36-A587-8329B3E0DE58Q48258257-4C17DB79-021A-4AC6-88FD-AD1D1EF36BE5Q50055342-21D3F06D-ED86-4ED4-975E-46E521B72108Q51283435-E9E5DFB9-A516-4E9A-85FC-05188D7549C1Q53064298-319D7382-0705-44BD-8589-A131586523A7Q54110867-9A44E3D2-F5C6-4804-9332-07B6CF6811BCQ60188546-B7EF2D86-26BC-4CBD-8834-6B2DC07EC0D9Q61712109-9CA5625E-A10D-4651-AEC3-394979E71FCBQ61818914-0901EF15-43EC-48AC-B1C1-C23B9295037FQ83703229-543384FB-B098-49FF-8D87-962F1D799EFEQ89446543-E3F9B072-5A6B-4058-B5D0-C1B901592B40Q92613353-2885FAEA-2771-4FF2-A96B-B8D74C7CCD70
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marie-Camille Chaumais
@ast
Marie-Camille Chaumais
@en
Marie-Camille Chaumais
@es
Marie-Camille Chaumais
@nl
type
label
Marie-Camille Chaumais
@ast
Marie-Camille Chaumais
@en
Marie-Camille Chaumais
@es
Marie-Camille Chaumais
@nl
prefLabel
Marie-Camille Chaumais
@ast
Marie-Camille Chaumais
@en
Marie-Camille Chaumais
@es
Marie-Camille Chaumais
@nl
P106
P31
P496
0000-0002-1217-8442